BI co-introduces cancer drug

By Ding Yining | July 3, 2015, Friday |

Online Edition

German pharmaceutical company Boehringer Ingelheim said it had signed a letter of intent with New York listed biopharmaceutical firm Provectus Biopharmaceuticals to co-introduce the latter's cancer drug PV-10 in China's mainland, Hong Kong and Taiwan, according to a joint statement yesterday.

Boehringer Ingelheim will provide support for the drug with the CFDA registration, marketing activities by leveraging its regulatory experience in China, as the company seeks to tap the growing demand of cancer medicines in the country.

"We're prepared to provide support for Provectus need to get PV-10 through the drug development and registration approval process in China," said Stephen Doyle, Vice President and Head of Specialty Care at Boehringer Ingelheim China.

Boehringer Ingelheim will enjoy the priority to be the exclusive collaborator of Provectus in China for PV-10 if the drug gets approved.

Business

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

BI co-introduces cancer drug

Email this to your friend